Testing Cancer Cell Drug Responses in Blood Cancers
Tests which drugs work on blood cancer cells from patients, to guide treatment choices.
Plain-language title generated from the registry record
Registry title: Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies
Key facts
- Where
- Zurich, SwitzerlandSee the site
Where in Switzerland
- University Children's Hospital ZurichZurich, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Children's Hospital, Zurich
- Trial code
- NCT06550102
- Record updated
- 15 August 2024
- Original description
This study is a prospective, non-randomized feasibility study of drug response profiling (DRP) in pediatric blood cancers. Primary cancer cells are isolated from patients and screened ex vivo at single-cell resolution using automated fluorescence microscopy. Drug sensitivity fingerprints are integrated with genetic annotations to inform the treating physician about personalized treatment options. The study aims to determine the practicability of real-time drug response profiling and its actionability in identifying patient-specific cancer dependencies in refractory disease settings.Read full original descriptionShow less
Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies
This study is a prospective, non-randomized feasibility study of drug response profiling (DRP) in pediatric blood cancers. Primary cancer cells are isolated from patients and screened ex vivo at single-cell resolution using automated fluorescence microscopy. Drug sensitivity fingerprints are integrated with genetic annotations to inform the treating physician about personalized treatment options. The study aims to determine the practicability of real-time drug response profiling and its actionability in identifying patient-specific cancer dependencies in refractory disease settings.
Inclusion: Pediatric and adult patients below the age of 40 years; Diagnosis of hematological malignancy (primary, relapsed or refractory) including leukemia, myeloma or lymphoma; Tumor material collected as part of routine diagnostics and willingness to donate tumor material for translational research; Patient and/or guardian has signed the informed consent of the DRP registry or of a clinical trial which includes DRP as add-on research.
Exclusion: Missing informed consent for the registry or of a clinical trial which includes DRP as add-on research.